Coherus Biosciences (CHRS) PT Lowered to $25 at JPMorgan
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.33 -0.75%
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
11 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
JPMorgan lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $25.00 (from $32.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) PT Raised to $250 at UBS Following Q1 Results
- Clear Secure Inc (YOU) PT Lowered to $45 at DA Davidson
- Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
